COMBINATION-BASED TREATMENT METHOD

1 . A method comprising the steps of: (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.

2 . The method of claim 1 , wherein the patient is suffering from a cancer.

3 . The method of claim 2 , wherein the cancer is a solid cancer.

4 . The method of claim 3 , wherein the solid cancer is selected from the group consisting of breast cancer, ovarian cancer, colon cancer, colorectal cancer, gastric cancer, malignant melanoma, liver cancer, small cell lung cancer, non-small cell lung cancer, thyroid cancers, kidney cancer, cancer of the bile duct, brain cancer, cervical cancer, maxillary sinus cancer, bladder cancer, esophageal cancer, Hodgkin's disease, adrenocortical cancer and Ewing sarcoma.

5 . The method of claim 2 , wherein the cancer is ovarian cancer.

6 . The method of claim 5 , wherein the ovarian cancer is platinum-resistant ovarian cancer.

7 . The method of claim 2 , wherein the cancer is colorectal cancer.

8 . The method of claim 2 , is breast cancer.

9 . The method of claim 2 , wherein the cancer is selected from group consisting of lymphoma cancers, leukemia cancers, rhabdomyosarcoma and neuroblastoma.

10 . The method of claim 1 , wherein the patient is human.

11 . The method of claim 1 , wherein step (a) is carried out prior to step (b) being carried out.

12 . The method of claim 1 , wherein (a) is carried out after step (b) is carried out.

13 . The method of claim 1 , wherein steps (a) and (b) are carried out simultaneously.

14 . The method of claim 1 , wherein each of steps (a) and (b) are carried out at least twice, followed by a maintenance phase wherein the patient is administered a PARP-inhibiting amount of a PARP inhibitor without any further administration of the long-acting topoisomerase I inhibitor.